As Lilly Seals Licensing Deals For Olumiant, What Next For Challenger Natco?

Lilly signs licensing pacts with Cipla, Sun and Lupin for baricitinib in COVID-19, with possibly more in store. But will challenger Natco, which has apparently already rolled out its cut-price version of the JAK inhibitor, change tack amid the Indian government's mixed position on compulsory licensing issues in an ongoing court case?

Lilly logo
Lilly Presses Ahead WIth India Licensing Deals For Baricitinib • Source: Alamy

Big pharma is pressing ahead with seeming urgency down the voluntary licensing path for key COVID-19 therapies in India.

After Merck & Co., Inc. struck deals for molnupiravir, Eli Lilly and Company has now firmed up voluntary...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia